MedPath

Therapeutic Innovation in Type 2 DIABetes (IT-DIAB)

Not Applicable
Conditions
Pre-diabetes
Registration Number
NCT01218061
Lead Sponsor
Nantes University Hospital
Brief Summary

The main objective of the study is to follow prospectively a cohort of patients with pre-diabetes to understand the pathophysiological mechanisms involved in switching from pre-diabetes to type 2 diabetes and to identify new biomarkers of type 2 diabetes risk in this population.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
366
Inclusion Criteria
  • Adult patients (≥18 years)
  • Subjects with diabetes risk score ≥ 15
  • Subjects with impaired fasting glucose: blood glucose ≥ 1.10 g/l and < 1 .26 g/L
  • Subjects affiliated with an appropriate social security system
Exclusion Criteria
  • Fasting glycemia ≥ 1.26 g/l
  • Fasting glycemia ≤ 1.10 g/l
  • Subjects previously treated with oral anti-diabetic: metformin, glitazones, inhibitors of α-glucosidase, sulfonylurea, repaglinide, inhibitors of DPP-IV, GLP-1 R agonists.
  • Subjects previously treated with insulin, except gestational diabetes
  • Severe coagulation disorders
  • Thrombocytopenia < 100 000/mm 3
  • Severe psychiatric disorders
  • Severe renal insufficiency (creatinine clearance < 30 ml/min)
  • Severe hepatic insufficiency (TP < 50%)
  • Alcohol abuse (> 30g/j)
  • Patient's opposition
  • Subject unable to follow the study during the 5 years of follow-up
  • Subject exclusion period in a previous study

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
The main objective of the study is to understand the pathophysiological mechanisms involved in switching from pre-diabetes to type 2 diabetes and to identify new biomarkers of type 2 diabetes risk in this population10 years

The main objective of the study is to follow prospectively a cohort of patients with pre-diabetes to understand the pathophysiological mechanisms involved in switching from pre-diabetes to type 2 diabetes and to identify new biomarkers of type 2 diabetes risk in this population

Secondary Outcome Measures
NameTimeMethod
Relation between "working hours and conditions" and metabolic disease10 years

To evaluate the impact of working hours and conditions on the prevalence of metabolic diseases (pre-diabetes, dyslipidemia...)

Number of patients with high Diabetes Risk Score and pre-diabetes10 years

To evaluate the interest of the Diabetes Risk Score in identifying subjects with pre-diabetes in the French population

Number of patients with others cardiovascular risk factors10 years

To evaluate the prevalence of others cardiovascular risk factors associated with pre-diabetes: dyslipidemia, hypertension, metabolic liver disease

HbA1c measurement10 years

To evaluate the role of HbA1C in screening for pre-diabetes and T2D

Number of patients with pre-diabetes10 years

To evaluate the prevalence of pre-diabetes in the region of Nantes

Trial Locations

Locations (1)

Nantes University Hospital

🇫🇷

Nantes, France

© Copyright 2025. All Rights Reserved by MedPath